Compare SATL & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SATL | XERS |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | 154 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | SATL | XERS |
|---|---|---|
| Price | $7.95 | $6.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $5.50 | ★ $10.83 |
| AVG Volume (30 Days) | ★ 7.9M | 1.6M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $88.89 | $34.37 |
| Revenue Next Year | $56.98 | $22.86 |
| P/E Ratio | ★ N/A | $626.50 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $1.26 | $4.30 |
| 52 Week High | $8.90 | $10.08 |
| Indicator | SATL | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 56.59 |
| Support Level | $3.17 | $6.26 |
| Resistance Level | $8.18 | $7.21 |
| Average True Range (ATR) | 0.75 | 0.29 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 69.81 | 48.39 |
Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.